Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Stefania Crisci, Raffaele Di Francia, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Rosaria De Filippi, Massimiliano Berretta, Paola Rossi, Antonio Pinto

Research output: Contribution to journalArticle

Abstract

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.
Original languageEnglish
Pages (from-to)443
Number of pages22
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - Jun 4 2019

Keywords

  • NHL
  • anticancer mAbs
  • personalized medicine
  • tailored therapy
  • tyrosine kinase inhibitors

Fingerprint Dive into the research topics of 'Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas'. Together they form a unique fingerprint.

  • Cite this